Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMCGATN)

Drug Name
Apabetalone Drug Info
Synonyms
RVX 000222; 1044870-39-4; 2-(4-(2-Hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one; RVX-000222; 2-[4-(2-Hydroxyethoxy)-3,5-Dimethylphenyl]-5,7-Dimethoxyquinazolin-4(3h)-One; UNII-8R4A7GDZ1D; RVX 000222; 8R4A7GDZ1D; QC-216; AK110565; Apabetalone [INN]; RVX000222; Apabetalone [USAN:INN]; 1K0; 4mr4; 4mr6; 4j1p; 4j3i; Apabetalone (USAN/INN); D0N7WW; SCHEMBL145019; GTPL7034; SCHEMBL17002023; AOB2133; DTXSID90146502; MolPort-027-835-445; NETXMUIMUZJUTB-UHFFFAOYSA-N; HMS3653C10; EX-A1110; BCP07787; ZINC4319
Cross-matching ID
PubChem CID
135564749
ChEBI ID
CHEMBL2393130
CAS Number
CAS 1044870-39-4
TTD Drug ID
D0F1JD

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Ribosome 2.17 0.00e+0 113/158 (71.52%) RPS4Y1;RPS5;RPL10A;...
DNA replication 1.99 0.00e+0 34/36 (94.44%) POLE3;RFC3;POLD3;...
Oxidative phosphorylation 1.88 3.05e-2 93/133 (69.92%) ATP5MF;PPA2;ATP5MC2;...
Huntington disease 1.83 2.85e-2 233/306 (76.14%) GRIA2;PLCB3;VDAC1;...
Mismatch repair 1.80 3.65e-2 22/23 (95.65%) RFC3;POLD3;RFC4;...
Amyotrophic lateral sclerosis 1.79 3.43e-2 267/364 (73.35%) GRIA2;NEFH;VDAC1;...
Circadian entrainment 1.78 3.10e-2 85/97 (87.63%) GRIA2;PLCB3;PER2;...
Oxytocin signaling pathway 1.75 4.14e-2 128/154 (83.12%) KRAS;SRC;PLCB3;...
Toll-like receptor signaling pathway -1.68 4.84e-2 94/104 (90.38%) MAPK14;PIK3CD;IFNA14;...
Legionellosis -1.71 4.27e-2 51/57 (89.47%) IL18;HSPA1A;ITGB2;...
Measles -1.71 4.61e-2 133/139 (95.68%) IFNA14;IL1B;TBK1;...
Protein digestion and absorption -1.72 4.43e-2 78/103 (75.73%) COL5A1;COL11A2;SLC7A9;...
Leishmaniasis -1.76 3.65e-2 67/77 (87.01%) HLA-DPA1;HLA-DQB1;CYBA;...
RIG-I-like receptor signaling pathway -1.76 4.18e-2 64/70 (91.43%) MAPK14;DHX58;IFNA14;...
Malaria -1.77 4.72e-2 44/50 (88%) IL1B;COMP;CD40;...
Pertussis -1.82 4.21e-2 64/76 (84.21%) NOD1;NLRP3;CASP1;...
ECM-receptor interaction -2.01 8.86e-3 80/88 (90.91%) ITGA1;ITGA9;COMP;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
VCaP CVCL_2235 Homo sapiens 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H